<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2026-11.3.19</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-6188</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Влияние мелатонина на неврологический статус и окислительную модификацию белков при экспериментальной церебральной ишемии</article-title><trans-title-group xml:lang="en"><trans-title>Effect of melatonin on neurological status and oxidative modification of proteins in experimental cerebral ischemia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6487-9083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осиков</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Osikov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осиков Михаил Владимирович – доктор медицинских наук, профессор, профессор РАН, заведующий кафедрой патофизиологии ФГБОУ ВО «Южно-Уральский ГМУ» Минздрава России; руководитель отдела научной работы ГБУЗ «Челябинская ОКБ».</p><p>454141, Челябинская область, Челябинск, ул. Воровского, 64; 454048, Челябинск, ул. Воровского, 70</p></bio><bio xml:lang="en"><p>Mikhail V. Osikov – Dr. Sc. (Med.), Professor, Professor of the RAS, Head of the Department of pathophysiology, South Ural SMU; Head of the Scientific Department at the Chelyabinsk Regional CH.</p><p>Vorovskogo st., 64, Chelyabinsk region, Chelyabinsk 454141; Vorovskogo st., 70, Chelyabinsk 454048</p></bio><email xlink:type="simple">prof.osikov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-1710-3922</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шеломенцев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shelomentsev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шеломенцев Алексей Викторович – аспирант кафедры патофизиологии ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России; врач-невролог ГБУЗ «Челябинский ОКТГ для ветеранов войн».</p><p>454141, Челябинская область, Челябинск, ул. Воровского, 64; 454048, Челябинск, ул. Медгородок, 8</p></bio><bio xml:lang="en"><p>Aleksey V. Shelomentsev – postgraduate student of the Department of pathophysiology, South Ural SMU; neurologist of the Chelyabinsk Regional Clinical Therapeutic Hospital for War Veterans.</p><p>Vorovskogo st., 64, Chelyabinsk region, Chelyabinsk 454141; Medgorodok str., 8, Chelyabinsk 454048</p></bio><email xlink:type="simple">avschelomenzew18@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8678-6267</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шишкова</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shishkova</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шишкова Юлия Сергеевна – доктор медицинских наук, профессор, профессор кафедры микробиологии, вирусологии и иммунологии.</p><p>454141, Челябинская область, Челябинск, ул. Воровского, 64</p></bio><bio xml:lang="en"><p>Yulia S. Shishkova – Dr. Sc. (Med.), Professor, Professor of the Department of microbiology, virology and immunology.</p><p>Vorovskogo st., 64, Chelyabinsk region, Chelyabinsk 454141</p></bio><email xlink:type="simple">shishkova_yulia@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2224-5175</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федосов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedosov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федосов Алексей Анатольевич – кандидат медицинских наук, доцент кафедры гистологии, цитологии и эмбриологии.</p><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Aleksey A. Fedosov – Cand. Sc. (Med.), associate professor at the Department of Histology, Cytology, and Embryology.MiklukhoMaklay St., 6, Moscow 117198</p></bio><email xlink:type="simple">fedosov.76@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет»; ГБУЗ «Челябинская областная клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University; Chelyabinsk Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет»; ГБУЗ «Челябинский областной клинический терапевтический госпиталь для ветеранов войн»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University; Chelyabinsk Regional Clinical Therapeutic Hospital for War Veterans</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples’ Friendship University of Russia named after Patrice Lumumba</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2026</year></pub-date><volume>11</volume><issue>3</issue><fpage>154</fpage><lpage>161</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Осиков М.В., Шеломенцев А.В., Шишкова Ю.С., Федосов А.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Осиков М.В., Шеломенцев А.В., Шишкова Ю.С., Федосов А.А.</copyright-holder><copyright-holder xml:lang="en">Osikov M.V., Shelomentsev A.V., Shishkova Y.S., Fedosov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/6188">https://www.actabiomedica.ru/jour/article/view/6188</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Ишемический инсульт (ИИ) остается одной из ведущих причин смертности и инвалидизации населения в мире. В связи с ограничениями перорального и парентерального пути введения нейропротекторов у постинсультных пациентов, применение ректальных суппозиториев с мелатонином (МТ) представляет собой перспективное направление нейропротективной терапии.</p></sec><sec><title>Цель</title><p>Цель. Оценить воздействие ректальных суппозиториев, содержащих МТ, на динамику изменений неврологического статуса и продуктов окислительной модификации белков при экспериментальной острой церебральной ишемии (ЭОЦИ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Крыс-самцов линии Wistar (30 особей) разделили на 3 группы: I – ложнooперированные животные; II – ЭOЦИ по методу Chen S.T. et al.; III – животные с ЭОЦИ, получавшие ректальные суппозитории массой 100 мг, содержащие 2,5 мг МТ. Неврологический статус изучали на 3-и 7-е сутки по шкале Гарсиа Дж.Н., тесту с постановкой лапки, Bederson test; в очаге церебральной ишемии (ОЦИ) оценивали содержание продуктов oкислительной модификации белков (ОМБ) (ранних и поздних).</p></sec><sec><title>Результаты</title><p>Результаты. У крыс с ЭOЦИ на соответствующие сутки развивался неврологический дефицит (уменьшение баллов по Гарсиа Дж.Н. и тесту с постановкой лапки, рост — по Bederson test) и повышение содержания продуктов ОМБ в ОЦИ. Введение суппозиториев с МТ способствовало регрессу указанных нарушений: к 7 суткам фиксировалось улучшение показателей всех неврологических тестов и снижение продуктов ОМБ в ОЦИ.</p><p>Выявлена отрицательная корреляционная зависимость между пoказателями пo шкале Гарсиа Дж.Н., тесту с постановкой лапки, Bederson test и прoдуктами OМБ в ОЦИ.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты позволяют предположить, что нейропротективное действие МТ в составе ректальных суппозиториев при ЭОИГМ реализуется через антиоксидантный механизм действия.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Ischemic stroke (IS) remains one of the leading causes of death and disability worldwide. Due to the limitations of oral and parenteral routes of neuroprotectant administration in post-stroke patients, the use of rectal suppositories with melatonin (MT) is a promising direction for neuroprotective therapy.</p></sec><sec><title>Aim</title><p>Aim. To evaluate the effect of rectal suppositories containing MT on the dynamics of neurological status and products of oxidative protein modification in experimental acute cerebral ischemia (EACI).</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Male Wistar rats (n = 30) were divided into 3 groups: I – sham-operated animals; II – animals with EACI according to the method of Chen S.T. et al.; III – animals with EACI that received rectal suppositories weighing 100 mg, containing 2.5 mg of MT. Neurological status was assessed on days 3 and 7 using the Garcia J.N. scale, the paw placement test, and the Bederson test. In the ischemic focus of the brain (IFB), the content of early and late products of protein oxidative modification (POM) was evaluated.</p></sec><sec><title>Results</title><p>Results. In rats with EACI, neurological deficits developed on the corresponding day (decreased scores on the Garcia J.N. scale and the paw placement test, increased scores on the Bederson test) and an increase in the content of POM products in the IFB. Administration of MT suppositories contributed to the regression of these disorders: by day 7, there was an improvement in all neurological tests, and a decrease in POM products in the IFB.</p></sec><sec><title>Conclusions</title><p>Conclusions. The results obtained suggest that the neuroprotective effect of MT in the form of rectal suppositories in EACI is mediated through an antioxidant mechanism of action.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>окислительный стресс</kwd><kwd>мелатонин</kwd><kwd>ректальные суппозитории</kwd><kwd>ишемический инсульт</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oxidative stress</kwd><kwd>melatonin</kwd><kwd>rectal suppositories</kwd><kwd>ischemic stroke</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World Stroke Organization: Global Stroke Fact Sheet 2025. Int J Stroke. 2025; 20(2): 132-144. doi: 10.1177/17474930241308142</mixed-citation><mixed-citation xml:lang="en">Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World Stroke Organization: Global Stroke Fact Sheet 2025. Int J Stroke. 2025; 20(2): 132-144. doi: 10.1177/17474930241308142</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральная служба государственной статистики (Росстат). Здравоохранение в России. 2025: Статистический сборник. Москва: Росстат; 2025: 200 с.</mixed-citation><mixed-citation xml:lang="en">Federal State Statistics Service (Rosstat). Healthcare in Russia. 2025: Statistical Digest. Moscow: Rosstat; 2025: 200 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Feske SK. Ischemic stroke. Am J Med. 2021; 134(12): 1457-1464. doi: 10.1016/j.amjmed.2021.07.027</mixed-citation><mixed-citation xml:lang="en">Feske SK. Ischemic stroke. Am J Med. 2021; 134(12): 1457-1464. doi: 10.1016/j.amjmed.2021.07.027</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update. Stroke. 2019; 50(12): e344-e418. doi: 10.1161/sTR.0000000000000211</mixed-citation><mixed-citation xml:lang="en">Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update. Stroke. 2019; 50(12): e344-e418. doi: 10.1161/sTR.0000000000000211</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Savitz SI, Baron JC, Fisher M, Hachinski V, Hakim AM, Hsu CY, et al. Reconsidering neuroprotection in the reperfusion era. Stroke. 2021; 52(2): 635-640. doi: 10.1161/sTROKEAHA.120.032599</mixed-citation><mixed-citation xml:lang="en">Savitz SI, Baron JC, Fisher M, Hachinski V, Hakim AM, Hsu CY, et al. Reconsidering neuroprotection in the reperfusion era. Stroke. 2021; 52(2): 635-640. doi: 10.1161/sTROKEAHA.120.032599</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pallab B, Bhattacharya D, Mukherjee R, Kumar H, Das S, Das SK. Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia. Life Sci. 2014; 100(2): 97-109. doi: 10.1016/j.lfs.2014.01.077</mixed-citation><mixed-citation xml:lang="en">Pallab B, Bhattacharya D, Mukherjee R, Kumar H, Das S, Das SK. Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia. Life Sci. 2014; 100(2): 97-109. doi: 10.1016/j.lfs.2014.01.077</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ma Q, Reiter RJ. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis. 2020; 23(2): 91-104. doi:10.1007/s10456-019-09689-7</mixed-citation><mixed-citation xml:lang="en">Ma Q, Reiter RJ. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis. 2020; 23(2): 91-104. doi:10.1007/s10456-019-09689-7</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Qin T, Li J, Wang Y, Hu F, Yang Y, Ren J, et al. Melatonin suppresses LPS-induced oxidative stress in dendritic cells for inflammatory regulation via the Nrf2/HO-1 axis. Antioxidants (Basel). 2022; 11(10): 2012. doi: 10.3390/antiox11102012</mixed-citation><mixed-citation xml:lang="en">Qin T, Li J, Wang Y, Hu F, Yang Y, Ren J, et al. Melatonin suppresses LPS-induced oxidative stress in dendritic cells for inflammatory regulation via the Nrf2/HO-1 axis. Antioxidants (Basel). 2022; 11(10): 2012. doi: 10.3390/antiox11102012</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Khedr EM, Abo El-Fetoh N, Alatter MA, Ali AM. Poststroke dysphagia: frequency, risk factors, and topographic representation: hospital-based study. Egypt J Neurol Psychiatr Neurosurg. 2021; 57: 23. doi: 10.1186/s41983-021-00279-3</mixed-citation><mixed-citation xml:lang="en">Khedr EM, Abo El-Fetoh N, Alatter MA, Ali AM. Poststroke dysphagia: frequency, risk factors, and topographic representation: hospital-based study. Egypt J Neurol Psychiatr Neurosurg. 2021; 57: 23. doi: 10.1186/s41983-021-00279-3</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zetner D, Andersen LPK, Alder R, Jessen ML, Tolstrup A, Rosenberg J. Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A CrossOver Study. Pharmacology. 2020; 105(9-10): 523-531. doi: 10.1159/000505234</mixed-citation><mixed-citation xml:lang="en">Zetner D, Andersen LPK, Alder R, Jessen ML, Tolstrup A, Rosenberg J. Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A CrossOver Study. Pharmacology. 2020; 105(9-10): 523-531. doi: 10.1159/000505234</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М.В. и др. Нейропротективный эффект мелатонина в составе оригинальных ректальных суппозиториев при экспериментальной острой ишемии головного мозга у крыс. Бюллетень экспериментальной биологии и медицины. 2025; 4: 431-436.</mixed-citation><mixed-citation xml:lang="en">Osikov MV, et al. Neuroprotective effect of melatonin in original rectal suppositories in experimental acute cerebral ischemia in rats. Bull Exp Biol Med. 2025; 4: 431-436 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М.В. и др. Ингибирование перекисного окисления липидов как механизм нейропротекторного действия мелатонина при экспериментальной острой ишемии головного мозга. Патологическая физиология и экспериментальная терапия. 2025; 69(4): 123-132. doi: 10.48612/pfiet/0031-2991.2025.04.123-132</mixed-citation><mixed-citation xml:lang="en">Osikov MV, et al. Inhibition of lipid peroxidation as a mechanism of neuroprotective action of melatonin in experimental acute cerebral ischemia. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 2025; 69(4): 123-132. (In Russ.). doi: 10.48612/pfiet/0031-2991.2025.04.123-132</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М.В. и др.; ФГБОУ ВО «Южно-Уральский государственный медицинский университет Минздрава России», патентообладатель. Средство с мелатонином для терапии воспалительных заболеваний кишечника в форме ректальных суппозиториев. Патент РФ № 2819721. 07.06.2024.</mixed-citation><mixed-citation xml:lang="en">Osikov MV, et al; South Ural State Medical University of the Ministry of Health of the Russian Federation, patentee. Melatonin-based agent for therapy of inflammatory bowel diseases in the form of rectal suppositories. Russian Federation Patent RU2819721. 2024 Jun 7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chen ST, Hsu CY, Hogan EL, Maricq H, Balentine JD. A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke. 1986; 17(4): 738-43. doi: 10.1161/01.STR.17.4.738</mixed-citation><mixed-citation xml:lang="en">Chen ST, Hsu CY, Hogan EL, Maricq H, Balentine JD. A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke. 1986; 17(4): 738-43. doi: 10.1161/01.STR.17.4.738</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia JH, Liu KF, Ho KL. Early reperfusion as a rationale form of therapy in ischemic stroke. Rev Neurol. 1995; 23(123): 1067-73.</mixed-citation><mixed-citation xml:lang="en">Garcia JH, Liu KF, Ho KL. Early reperfusion as a rationale form of therapy in ischemic stroke. Rev Neurol. 1995; 23(123): 1067-73.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schallert T, Woodlee MT, Fleming SM. The behavior of the laboratory rat: a handbook with tests. New York: Oxford University Press; 2005: 129-40. doi: 10.1093/acprof:oso/9780195162851.001.0001</mixed-citation><mixed-citation xml:lang="en">Schallert T, Woodlee MT, Fleming SM. The behavior of the laboratory rat: a handbook with tests. New York: Oxford University Press; 2005: 129-40. doi: 10.1093/acprof:oso/9780195162851.001.0001</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17(3): 472-6. doi: 10.1161/01.STR.17.3.472</mixed-citation><mixed-citation xml:lang="en">Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17(3): 472-6. doi: 10.1161/01.STR.17.3.472</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">18. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20(1): 84-91. doi: 10.1161/01.STR.20.1.84</mixed-citation><mixed-citation xml:lang="en">18. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20(1): 84-91. doi: 10.1161/01.STR.20.1.84</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Фомина М.А. и др. Способ комплексной оценки содержания продуктов окислительной модификации белков в тканях и биологических жидкостях. Патент RU 2524667 C1. 2014</mixed-citation><mixed-citation xml:lang="en">Fomina MA, et al. Method complex assessment of product content of oxidative modification of proteins in tissues and biological fluids. Patent RU 2524667 C1. 2014. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Львовская Е.И. и др. Спектрофотометрическое определение конечных продуктов перекисного окисления липидов. Вопросы медицинской химии. 1991; 37(4): 92-3.</mixed-citation><mixed-citation xml:lang="en">Lvovskaya EI, et al. Spectrophotometric determination of final products of lipid peroxidation. Vopr Med Khim. 1991; 37(4): 92-3. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Angelova PR, Abramov AY, Bianchi C, Bolea I, Caruso G, Chmura N, et al. Functional role of mitochondrial reactive oxygen species in physiology and pathology. Cell Calcium. 2023; 112: 102734.</mixed-citation><mixed-citation xml:lang="en">Angelova PR, Abramov AY, Bianchi C, Bolea I, Caruso G, Chmura N, et al. Functional role of mitochondrial reactive oxygen species in physiology and pathology. Cell Calcium. 2023; 112: 102734.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Gimenez JL, Roma-Mateo C, Carbonell N, Palacios L, Moreno ML, Markovic J, et al. Oxidative stress-mediated alterations in histone post-translational modifications. Free Radic Biol Med. 2021; 170: 6-18. doi: 10.1016/j.freeradbiomed.2021.03.037</mixed-citation><mixed-citation xml:lang="en">Garcia-Gimenez JL, Roma-Mateo C, Carbonell N, Palacios L, Moreno ML, Markovic J, et al. Oxidative stress-mediated alterations in histone post-translational modifications. Free Radic Biol Med. 2021; 170: 6-18. doi: 10.1016/j.freeradbiomed.2021.03.037</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tesoriero L, Rossi R, et al. Protein actin carbonylation: from a simple marker of oxidation to relevant player in cell pathophysiology. Redox Biol. 2023; 59: 102576. doi: 10.1016/j.redox.2022.102576</mixed-citation><mixed-citation xml:lang="en">Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tesoriero L, Rossi R, et al. Protein actin carbonylation: from a simple marker of oxidation to relevant player in cell pathophysiology. Redox Biol. 2023; 59: 102576. doi: 10.1016/j.redox.2022.102576</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Weber D, Davies MJ, Grune T, Sitte N, Jung T. Protein carbonylation as a biomarker of oxidative stress in age-related diseases. Aging Cell. 2023; 22(2): e13769. doi: 10.1111/acel.13769</mixed-citation><mixed-citation xml:lang="en">Weber D, Davies MJ, Grune T, Sitte N, Jung T. Protein carbonylation as a biomarker of oxidative stress in age-related diseases. Aging Cell. 2023; 22(2): e13769. doi: 10.1111/acel.13769</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Madian AG, Regnier FE, Harrison EH, Lee BC, Kim JY. Proteomic identification of carbonylated proteins and their oxidation sites. J Proteome Res. 2020; 19(1): 23-32. doi: 10.1021/acs.jproteome.9b00519</mixed-citation><mixed-citation xml:lang="en">Madian AG, Regnier FE, Harrison EH, Lee BC, Kim JY. Proteomic identification of carbonylated proteins and their oxidation sites. J Proteome Res. 2020; 19(1): 23-32. doi: 10.1021/acs.jproteome.9b00519</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Zhou XJ, Xu B. Melatonin as a mitochondria-targeted antioxidant: one molecule, many functions. Cell Mol Life Sci. 2023; 80(5): 127. doi: 10.1007/s00018-023-04736-5</mixed-citation><mixed-citation xml:lang="en">Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Zhou XJ, Xu B. Melatonin as a mitochondria-targeted antioxidant: one molecule, many functions. Cell Mol Life Sci. 2023; 80(5): 127. doi: 10.1007/s00018-023-04736-5</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Galano A, Reiter RJ. Melatonin and its metabolites vs. oxidative stress: from individual actions to collective protection. J Pineal Res. 2022; 73(1): e12818. doi: 10.1111/jpi.12818</mixed-citation><mixed-citation xml:lang="en">Galano A, Reiter RJ. Melatonin and its metabolites vs. oxidative stress: from individual actions to collective protection. J Pineal Res. 2022; 73(1): e12818. doi: 10.1111/jpi.12818</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Che H, Wang Y, Li H, Wang Y, Zhang J, Li X. Melatonin exerts neuroprotective effects by inhibiting neuronal pyroptosis and autophagy in STZ-induced diabetic mice. FASEB J. 2021; 35(4): e21454. doi: 10.1096/fj.202002600R</mixed-citation><mixed-citation xml:lang="en">Che H, Wang Y, Li H, Wang Y, Zhang J, Li X. Melatonin exerts neuroprotective effects by inhibiting neuronal pyroptosis and autophagy in STZ-induced diabetic mice. FASEB J. 2021; 35(4): e21454. doi: 10.1096/fj.202002600R</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
